Corcept's Relacorilant Nears EU Approval for Ovarian Cancer Treatment
Event summary
- CHMP recommends EU marketing authorization for relacorilant combined with nab-paclitaxel for platinum-resistant ovarian cancer.
- Recommendation based on positive Phase 2 and Phase 3 ROSELLA trial data showing improved progression-free and overall survival.
- European Commission to issue final decision in Q4 2026.
- Relacorilant is already FDA-approved in the U.S. under the trade name Lifyorli®.
The big picture
Corcept's potential EU approval for relacorilant marks a significant step in expanding its reach beyond the U.S. market. The drug's unique mechanism of targeting cortisol's role in tumor growth could position it as a key player in the treatment of platinum-resistant ovarian cancer, a condition with limited therapeutic options. The strategic shift towards cortisol modulation in oncology aligns with broader industry trends in precision medicine and targeted therapies.
What we're watching
- Regulatory Timing
- Whether the European Commission will approve relacorilant by the end of Q4 2026 as anticipated.
- Market Expansion
- How quickly Corcept can penetrate the EU market with relacorilant following approval.
- Competitive Dynamics
- Whether relacorilant's selective glucocorticoid receptor modulation will differentiate it from existing treatments.
Related topics